{"id":195048,"name":"AMERISOURCEBERGEN CORPORATION","slug":"amerisourcebergen-corporation","state":"DC","description":"pharmaceuticals","totalSpending":1490000,"filings":19,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":320000},{"year":2020,"income":400000},{"year":2021,"income":320000},{"year":2022,"income":210000}],"firms":["ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)"],"lobbyists":["STEVEN IRIZARRY","VINCENT ROBERTI, SR."],"issues":["TAX","MMM","PHA"],"sampleDescriptions":["- Issues related to LIFO (last in, first out)","- Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction) \n- Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463)","- Legislation to prevent and reduce prescription drug abuse; Ensuring Patient Access and Effective Drug Enforcement Act (Pub.L. 114-145)\n- Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies\n- Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54)\n- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771)\n- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally\nLegislation to exclude cancer drugs from sequestration cuts","Legislation to prevent and reduce prescription drug abuse; Ensuring Patient Access and Effective Drug Enforcement Act (Pub.L. 114-145)\nLegislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies\nIssues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA\nHHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. \nIssues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771)\nIssues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); \nASP, generally\nMedicare Part D, including removal of safe harbor protection for drug rebates\nMedicare Part B, including proposals to create an international pricing index, establish a competitive acquisition program","Legislation to prevent and reduce prescription drug abuse\nLegislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies\nIssues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA\nIssues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs\nIssues related to drug pricing, generally\nIssues related to the importation of prescription medicines","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).\nASP, generally\nIssues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs \nMedicare Part D, including removal of safe harbor protection for drug rebates\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program","S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. \nIssues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA.\nIssues related to drug pricing and transparency, generally.\nIssues related to the importation of prescription medicines","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).\nASP, generally\nIssues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs \nMedicare Part D, including removal of safe harbor protection for drug rebates\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program\nPrescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.","Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts Medicare Accelerated and Advance Payment Program \n\nMedicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP)\nMedicare Part D, including the removal of safe harbor protections for drug rebates\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program\nPrescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B\nASP, generally\nIssues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs","Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts SBA Paycheck Protection Program\nS. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. \nIssues related to drug pricing and transparency, generally.\nIssues related to the importation of prescription medicines","Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts SBA Paycheck Protection Program\nS. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. \nIssues related to drug pricing and transparency, generally.\nIssues related to the importation of prescription medicines\nIssues related to the pharmaceutical supply chain","Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA.\n.      Issues related to drug pricing and transparency, generally.\nIssues related to the importation of prescription medicines\nIssues related to the pharmaceutical supply chain and stockpiling\nIssues related to COVID vaccine distribution\nTax issues related to Puerto Rico","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).\nASP, generally\nMedicare Part D, including removal of safe harbor protection for drug rebates\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program\nPrescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.\nS. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).\nASP, generally\nMedicare Part D, including removal of safe harbor protection for drug rebates\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program\nPrescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.","S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA.\n       Issues related to drug pricing and transparency, generally.\nIssues related to the importation of prescription medicines\nIssues related to the pharmaceutical supply chain and stockpiling\nIssues related to COVID vaccine distribution","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).\nSequestration, generally\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program\nMedicare Part D, including removal of safe harbor protection for drug rebates\nPrescription drug pricing, value, and transparency, generally","Issues related to drug pricing and transparency, generally.\nIssues related to the importation of prescription medicines\nIssues related to the pharmaceutical supply chain and stockpiling\nIssues related to COVID vaccine distribution"],"years":[2018,2019,2020,2021,2022]}